Live MediSum Demo

In 38 heavily pretreated patients with relapsed or refractory B‑cell non‑Hodgkin lymphomas (24 large B‑cell, 14 follicular) treated once with tisagenlecleucel and followed for a median of 10.1 years, no relapses occurred beyond 5.4 years. Ten‑year lymphoma‑free survival was 32% (95% CI 14–51) for large B‑cell lymphoma and 47% (95% CI 20–71) for follicular lymphoma; 10‑year overall survival was 17% and 50%, respectively, with persistent B‑cell aplasia in 44% of long‑term responders, a 10‑year cumulative incidence of second primary cancers of 21%, and low rates of late cytopenias.

In 34 pediatric patients (ages 0–17) with low-grade gliomas, glioneuronal tumors, and high-grade gliomas, immunohistochemistry showed CAIX expression in 58.8% of tumors with no significant enrichment in HGGs versus LGG/GNT. Tumors frequently expressed monocyte/macrophage markers (CD68, CD44, CD163, CCR2) but had low PD-1/PD-L1 expression; CAIX correlated positively with CD44 (p=0.01) and CD206 (p=0.009). Strong CD68 expression (>30%) was associated with better 2-year event-free survival (91.7% vs 53.8%; p=0.011), while CAIX and other immune markers were not significantly associated with EFS.

In a phase 1 study of 18 older adults (≥55 years, median age 64) with B-ALL in first complete remission, memory-enriched CD19 CAR T cells after lymphodepletion were administered as definitive consolidation and produced detectable CAR T-cell expansion in blood and cerebrospinal fluid. Treatment had no dose-limiting toxicities, no grade ≥2 cytokine release syndrome and no immune effector cell-associated neurotoxicity, with estimated 18-month event-free and overall survival of 84% and 100%, respectively, supporting safety and potential durability of early CAR T use in this cohort.